Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy

• Päätekijät: Amelia C. McCue (Tekijä), Stephen J. Demarest (Tekijä), Karen J. Froning (Tekijä), Michael J. Hickey (Tekijä), Stephen Antonysamy (Tekijä), Brian Kuhlman (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

T-cell engaging (TCE) bispecific antibodies are potent drugs that trigger the immune system to eliminate cancer cells, but administration can be accompanied by toxic side effects that limit dosing. TCEs function by binding to cell surface receptors on T cells, frequently CD3, with one arm of the bis...